Institute for Clinical & Economic Review Publishes Evidence Report on Treatments for Obesity Management
September 01, 2022
September 01, 2022
BOSTON, Massachusetts, Sept. 1 (TNSrpt) -- The Institute for Clinical and Economic Review issued the following news release on Aug. 31, 2022:
* * *
Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide and with bupropion/naltrexone
The value of semaglutide used for weight loss would achieve common thresholds for cost-effectiveness if priced between $7,500 - $9,800 per year; phentermine/topi . . .
* * *
Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide and with bupropion/naltrexone
The value of semaglutide used for weight loss would achieve common thresholds for cost-effectiveness if priced between $7,500 - $9,800 per year; phentermine/topi . . .